Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Pacira BioSciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 FIRST PATIENT ENROLLED IN PART B OF PHASE 2 ASCEND STUDY ENABLED BY AVAILABILITY OF DRUG PRODUCT FROM NEW MANUFACTURING PROCESS   TOPLINE DATA FROM PART A OF PHASE 2 ASCEND STUDY REMAINS ON TRACK FOR END OF YEAR  BRISBANE, CALIF., JULY 27, 2026 (GLOBE NEWSWIRE) -- PACIRA BIOSCIENCES, INC. (NASDAQ: PCRX), THE INDUSTRY LEADER IN ITS COMMITMENT TO DELIVER INNOVATIVE, NON-OPIOID PAIN THERAPIES TO TRANSFORM THE LIVES OF PATIENTS, TODAY ANNOUNCED THAT IT HAS SUCCESSFULLY TRANSITIONED PCRX-201 (ENEKINRAGENE INZADENOVEC), ITS INVESTIGATIONAL LOCALLY ADMINISTERED GENE THERAPY FOR OSTEOARTHRITIS OF THE KNEE, TO A U.S.-BASED SCALABLE COMMERCIAL MANUFACTURING PROCESS INTENDED TO SUPPORT FUTURE REGISTRATIONAL DEVELOPMENT AND COMMERCIALIZATION.

PACIRA BIOSCIENCES ADVANCES PCRX-201 DEVELOPMENT PROGRAM WITH SUCCESSFUL TRANSITION TO SCALABLE COMMERCIAL MANUFACTURING PROCESS

BRISBANE, CALIF., JULY 22, 2026 (GLOBE NEWSWIRE) -- PACIRA BIOSCIENCES, INC. (NASDAQ: PCRX), THE INDUSTRY LEADER IN ITS COMMITMENT TO DELIVER INNOVATIVE, NON-OPIOID PAIN THERAPIES TO TRANSFORM THE LIVES OF PATIENTS, TODAY ANNOUNCED THAT IT WILL REPORT ITS SECOND QUARTER 2026 FINANCIAL RESULTS AFTER THE CLOSE OF THE U.S. MARKETS ON TUESDAY AUGUST 4, 2026. FOLLOWING THE RELEASE, THE COMPANY WILL HOST A LIVE CONFERENCE CALL AND WEBCAST AT 4:30 P.M. ET.

PACIRA TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS ON TUESDAY AUGUST 4, 2026

BRISBANE, CALIF., JULY 08, 2026 (GLOBE NEWSWIRE) -- PACIRA BIOSCIENCES, INC. (NASDAQ: PCRX), THE INDUSTRY LEADER IN THE DELIVERY OF INNOVATIVE, NON-OPIOID PAIN THERAPIES TO TRANSFORM THE LIVES OF PATIENTS, TODAY ANNOUNCED THE GRANTING OF INDUCEMENT AWARDS ON JULY 2, 2026 TO TEN NEW EMPLOYEES UNDER PACIRA'S AMENDED AND RESTATED 2014 INDUCEMENT PLAN (THE INDUCEMENT PLAN) AS A MATERIAL INDUCEMENT TO EACH EMPLOYEE'S ENTRY INTO EMPLOYMENT WITH THE COMPANY. IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4), THE AWARDS WERE APPROVED BY THE PEOPLE & COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS (THE COMMITTEE) WITHOUT STOCKHOLDER APPROVAL.

PACIRA BIOSCIENCES REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

-- EXPANDS PATIENT ACCESS TO NON-OPIOID POSTSURGICAL PAIN MANAGEMENT ACROSS OUTPATIENT SETTINGS -- BRISBANE, CALIF., JULY 01, 2026 (GLOBE NEWSWIRE) -- PACIRA BIOSCIENCES, INC. (NASDAQ: PCRX), THE INDUSTRY LEADER IN ITS COMMITMENT TO DELIVER INNOVATIVE, NON-OPIOID PAIN THERAPIES TO TRANSFORM THE LIVES OF PATIENTS, TODAY ANNOUNCED THAT UNITEDHEALTHCARE NOW PROVIDES SEPARATE REIMBURSEMENT FOR EXPAREL (BUPIVACAINE LIPOSOME INJECTABLE SUSPENSION) ACROSS OUTPATIENT SETTINGS, INCLUDING HOSPITAL OUTPATIENT DEPARTMENTS AND AMBULATORY SURGERY CENTERS.

PACIRA BIOSCIENCES ANNOUNCES UNITEDHEALTHCARE NOW PROVIDES SEPARATE REIMBURSEMENT FOR EXPAREL

-- PACIRA TO RECEIVE UP TO $140 MILLION WITH $70 MILLION UPFRONT AND UP TO AN ADDITIONAL $70 MILLION IN POTENTIAL FUTURE REVENUE-BASED MILESTONE PAYMENTS -- -- TWO COMPANIES WILL COLLABORATE ON ADVANCING THE SPASTICITY PROGRAM --

PACIRA BIOSCIENCES ANNOUNCES AGREEMENT TO DIVEST ITS IOVERA BUSINESS TO ZIMMER BIOMET

BRISBANE, CALIF., JUNE 9, 2026 /PRNEWSWIRE/ -- PACIRABIOSCIENCES, INC. (NASDAQ:PCRX) (THE "COMPANY" OR "PACIRA"), THE INDUSTRY LEADER IN ITS COMMITMENT TO DELIVER INNOVATIVE, NON-OPIOID PAIN THERAPIES TO TRANSFORM THE LIVES OF PATIENTS, TODAY ANNOUNCED THAT BASED ON THE PRELIMINARY RESULTS OF ITS 2026 ANNUAL MEETING OF STOCKHOLDERS (THE "ANNUAL MEETING") PROVIDED BY ITS PROXY SOLICITOR, D.F.

PACIRA BIOSCIENCES ANNOUNCES STOCKHOLDERS HAVE ELECTED ALL THREE OF THE COMPANY'S DIRECTOR NOMINEES AT ANNUAL MEETING

ELECTION OF EVEN A SINGLE DOMA NOMINEE WOULD RISK COMPROMISING PACIRA'S STRONG FORWARD MOMENTUM LEADING INDEPENDENT EXPERTS ISS, GLASS LEWIS AND EGAN-JONES AGREE THAT DOMA REPRESENTATION IS NOT WARRANTED BRISBANE, CALIF., JUNE 4, 2026 /PRNEWSWIRE/ -- PACIRABIOSCIENCES, INC. (NASDAQ: PCRX) (THE "COMPANY" OR "PACIRA"), THE INDUSTRY LEADER IN ITS COMMITMENT TO DELIVER INNOVATIVE, NON-OPIOID PAIN THERAPIES TO TRANSFORM THE LIVES OF PATIENTS, TODAY ISSUED A REMINDER TO ALL PACIRA STOCKHOLDERS TO VOTE THE BLUE PROXY CARD "FOR" EACH OF PACIRA'S THREE HIGHLY QUALIFIED DIRECTOR NOMINEES IN ADVANCE OF THE COMPANY'S UPCOMING 2026 ANNUAL MEETING OF STOCKHOLDERS (THE "ANNUAL MEETING") ON JUNE 9, 2026.

PACIRA BIOSCIENCES REMINDS STOCKHOLDERS TO VOTE THE BLUE PROXY CARD "FOR" THE ELECTION OF THE COMPANY'S HIGHLY QUALIFIED NOMINEES AHEAD OF ITS ANNUAL MEETING

ISS CONCLUDES "THERE IS A COMPELLING REASON TO SUPPORT ALL MANAGEMENT NOMINEES" AND NOTES "THE DISSIDENT HAS NOT PRESENTED A COMPELLING CASE FOR CHANGE" BRISBANE, CALIF., JUNE 1, 2026 /PRNEWSWIRE/ -- PACIRA BIOSCIENCES, INC. (NASDAQ: PCRX) (THE "COMPANY" OR "PACIRA"), THE INDUSTRY LEADER IN ITS COMMITMENT TO DELIVER INNOVATIVE, NON-OPIOID PAIN THERAPIES TO TRANSFORM THE LIVES OF PATIENTS, TODAY ANNOUNCED THAT LEADING INDEPENDENT PROXY ADVISORY FIRM INSTITUTIONAL SHAREHOLDER SERVICES, INC. ("ISS") HAS RECOMMENDED THAT PACIRA STOCKHOLDERS VOTE "FOR" EACH OF PACIRA'S THREE DIRECTOR NOMINEES  CHRISTOPHER CHRISTIE, SAMIT HIRAWAT, MD AND THOMAS WIGGANS  AND "AGAINST" ALL THREE OF DOMA PERPETUAL CAPITAL MANAGEMENT LLC'S ("DOMA PERPETUAL" OR "DOMA")1NOMINEES ON THE BLUE PROXY CARD AHEAD OF THE COMPANY'S 2026 ANNUAL MEETING OF STOCKHOLDERS (THE "ANNUAL MEETING") ON JUNE 9, 2026.

PACIRA BIOSCIENCES HIGHLIGHTS LEADING INDEPENDENT PROXY ADVISORY FIRM ISS' RECOMMENDATION TO VOTE "FOR" ALL OF PACIRA'S DIRECTOR NOMINEES

FIRST QUARTER 2026 REVENUE UP 79.4% COMPARED TO THE FIRST QUARTER OF 2025 FIRST QUARTER 2026 GROSS PROFIT INCREASED 71.9% COMPARED TO THE FIRST QUARTER OF 2025 FIRST QUARTER SAME-STORE SALES WERE UP 7.3%, AND SAME-STORE PRESCRIPTION SALES WERE UP 7.2%, BOTH COMPARED TO THE FIRST QUARTER OF 2025 SASKATOON, SASKATCHEWAN, JUNE 01, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC.(PHARMACORP OR THE CORPORATION) (TSXV: PCRX) A CANADIAN PHARMACY SERVICES AND CONSOLIDATION PLATFORM, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026.

PHARMACORP RX INC. ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS

BRISBANE, CALIF., MAY 28, 2026 (GLOBE NEWSWIRE) -- PACIRA BIOSCIENCES, INC. (NASDAQ: PCRX) (THE COMPANY OR PACIRA), THE INDUSTRY LEADER IN ITS COMMITMENT TO DELIVER INNOVATIVE, NON-OPIOID PAIN THERAPIES TO TRANSFORM THE LIVES OF PATIENTS, TODAY ANNOUNCED THAT LEADING INDEPENDENT PROXY ADVISORY FIRM GLASS LEWIS & CO., LLC (GLASS LEWIS) HAS RECOMMENDED THAT PACIRA STOCKHOLDERS VOTE FOR EACH OF PACIRA'S THREE DIRECTOR NOMINEES  CHRISTOPHER CHRISTIE, SAMIT HIRAWAT, MD AND THOMAS WIGGANS  AND AGAINST ALL THREE OF DOMA PERPETUAL CAPITAL MANAGEMENT LLC'S (DOMA PERPETUAL OR DOMA)1 NOMINEES ON THE BLUE PROXY CARD AHEAD OF THE COMPANY'S 2026 ANNUAL MEETING OF STOCKHOLDERS (THE ANNUAL MEETING) ON JUNE 9, 2026.

Pacira BioSciences, Inc.

PCRX

Price

Financial Reports

No items found.

Press Releases

Pacira BioSciences, Inc.

PCRX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

PCRX